Search company, investor...



Other Investors | Alive

About Neurotex

Neurotex has been established to develop silk-based products providing nerve repair meterials.

Headquarters Location

The Garden House Southdown Road, Shawford

SO21 2BX,

United Kingdom

Missing: Neurotex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neurotex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Neurotex Patents

Neurotex has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Neurological disorders, Neurotrauma, Peripheral nervous system disorders, Rare diseases, Neurology


Application Date


Grant Date



Related Topics

Neurological disorders, Neurotrauma, Peripheral nervous system disorders, Rare diseases, Neurology



Neurotex Frequently Asked Questions (FAQ)

  • What is Neurotex's latest funding round?

    Neurotex's latest funding round is Other Investors.

  • Who are the investors of Neurotex?

    Investors of Neurotex include Kinetique Biomedical Seed Fund and Javelin Venture Partners.

  • Who are Neurotex's competitors?

    Competitors of Neurotex include Sonoma Orthopedic Products, NeoGraft Technologies, Fournitures Hospitalieres, Biomimedica, AxoGen and 13 more.

Compare Neurotex to Competitors

PeriTec Biosciences

PeriTec is a Cleveland, Ohio based company that aims to develop vascular and cardiovascular surgical products. The company's technology involves the incorporation of a biological tissue, peritoneum, into implantable peripheral vascular stents and vascular patches.

NeoGraft Technologies

NeoGraft Technologies is developing Angioshield, an intraperative system that creates a micro-fibrous, polymer sleeve intimately surrounding the outside surface of a harvested vein to mechanically reinforce and protect it from overdilation.


Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.

CleveX Logo

CleveX Inc. is a medical device company that is developing and marketing skin biopsy closure and repair solutions for the dermatology cosmetic surgery and primary care physicians. CleveX (LLC) started out in 2004 as a joint venture between Cleveland Clinic Foundation (Cleveland OH) and IDx Medical Design (Cincinnati OH) to develop and commercialize surgical dermatology and skin repair innovations generated by leading physicians at the Cleveland Clinic. The company's lead technology platform is the ExiClip. The ExiClip is a single-step disposable surgical device that efficiently excises a skin lesion while simultaneously closing and repairing the surgical site.

Connective Orthopaedics

Connective Orthopaedics is a medical device company focused on the repair of soft tissue injuries.

OmniSonics Medical Technologies

OmniSonics was a medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.